---
document_datetime: 2026-02-20 13:46:30
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/apremilast-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: apremilast-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7889878
conversion_datetime: 2026-02-21 12:44:51.310278
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## Apremilast Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                            |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------|
| Variation type IB /  | C. Safety, efficacy, pharmacovigilance | 19/02/2026                          |                                             | SmPC and PL                      | To update section 4.4 of the SmPC and section 2 of |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000326527                     | changes - C.z Other variation - Accepted C.z (Type IB) - To update section 4.4 of the SmPC and section 2 of the PL to include the missing excipient warning for sodium, in line with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. The MAH has also made several editorial updates in line with the QRD template. Section9 of the SmPC now includes the date of first authorisation, and section10 has been updated with the correct EMA website address. In section 4.8, t he wording on the 'national reporting system listed in AppendixV' has been revised and grey shaded. In the PL, section6 has been updated to add the relevant E numbers for   |            |           | the PL to include the missing excipient warning for sodium, in-line with the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'. The MAH has also made several editorial updat es in line with the QRD template. Section9 of the SmPC now includes the date of first authorisation, and section10 has been updated with the correct EMA website address. In section 4.8, the wording on the 'national reporting system listed in AppendixV' has been revised and grey shaded. In the PL, section6 has been updated to add the relevant E numbers for excipients, in line with the SmPC.   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000321370 | B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.a Up to 10-fold compared to the originally approved batch size - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/01/2026 |           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Article 61(3) / EMA/N/0000317881      | - Notification acc. Article 61(3) - Accepted Update of the product information to introduce the following changes to the labelling: - to align the grey-shading of the pharmaceutical form in section '4. Pharmaceutical form and contents' of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 07/01/2026 | Labelling |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                                       | 'Particulars to appear on the outer packaging' with all other presentations - to update 'For oral use' to 'Oral use' in section '5. Method and route(s) of administration' of the 'Particulars to appear on the outer packaging' - to grey-shade all blister text of the 'Minimum particulars to appear on blisters or strips' for the wallet card initiation packs - to align the grey-shading of '2D barcode carrying the unique identifier included' in section '17. Unique identifier -2D barcode' of the 'Particulars to appear on the outer packaging' with all other presentations. - to harmonise the grey- shading of the marketing authorisation number in section '12. Marketing authorisation number(s)' of the 'Particulars to appear on the outer packaging' where applicable. Additionally, the MAH took the opportunity to introduce minor editorial   |            |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Variation type IA / EMA/VR/0000280853 | This was an application for a group of variations. A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 25/06/2025 |

<div style=\"page-break-after: always\"></div>

| A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|